Gordon C. McCauley, President and CEO
Gordon McCauley was appointed President & CEO of CDRD in 2017 after serving on the Board for four years. Mr. McCauley is an accomplished life science investor and executive.
He has served as President & CEO of Viable Healthworks Corp., a national healthcare service business; President and CEO of Allon Therapeutics Inc., a neuroscience biotechnology company that developed novel therapeutics from pre-clinical to global phase 3 studies before being sold, and Co-Founder and Partner of NDI Capital, an institutionally-backed life-science investment fund. Mr. McCauley has also been a senior executive of several successful health care enterprises and a senior advisor to several prominent Canadian political leaders.
Mr. McCauley is a Director of Defender Therapeutics, Inc., and 3D Signatures Inc. He is also a Director of LifeSciences British Columbia and served as its Chair from 2012 – 2015, and a Director of BioteCanada. In 2008 Mr. McCauley was the first Canadian appointed to the Board of The Biotechnology Industry Organization (BIO) in Washington D.C., where he served in leadership positions until 2013. He is Past Chair of Acetech, and was a founding Director of the Toronto Rehabilitation Institute and Past Chair of the Toronto Rehab Foundation.
Matthew J. Carlyle, Chief Financial Officer
Matthew Carlyle was appointed Chief Financial Officer in May, 2017. Mr. Carlyle brings extensive experience and relationships across global biotechnology and venture capital to CDRD, having been a partner of a national venture capital firm, CFO of a publicly traded biotech, and CFO of a number of private life sciences companies.
Most recently, Mr. Carlyle was the Chief Financial Officer of Viable Healthworks Corp., and from 2004 to 2013, was Chief Financial Officer of Allon Therapeutics Inc. Previously, he served in Corporate Finance and Development roles for a number of public and private life science and technology companies, and has been involved in raising approximately $200M. Mr. Carlyle is a founding Partner of NDI Capital, a private investment management company focused on investing in high potential life science and healthcare companies. He holds the Chartered Financial Analyst designation and is a member of the Association for Investment Management and Research, and the Vancouver Society of Financial Analysts.
Jason Crawford, Vice President, Scientific Operations
As the Vice President of Scientific Operations at The Centre for Drug Research and Development (CDRD), Canada’s fully-integrated national drug development and commercialization centre, Dr. Crawford plays a key role in the evaluation of potential drug development projects to be incubated within CDRD, and holds responsibility for the successful execution of all subsequent project development plans, and thus the overall management of CDRD’s scientific resources. Prior to assuming this role, he was Head of Medicinal Chemistry at CDRD, having joined the organization in 2008.
Previously, from 1999-2007, he held a series of increasingly-senior positions at AnorMED Inc. – initially a Medicinal Chemist, and eventually the Manager of the Development Chemistry Group, leading the synthetic development of all lead and candidate compounds intended for use in pre-clinical and clinical trials. Notably, for plerixafor, which now generates over $150 million annually in global sales as Mozobil, he oversaw the technical transfer of the development process to a contract research organization, the subsequent clinical manufacture, and the eventual validation of the manufacturing process for commercial use. He also acted concurrently as an interdisciplinary project team leader for a clinical-stage anti-HIV therapeutic. In addition to his experience at AnorMED, Dr. Crawford also developed novel antibacterial agents in his role of Senior Scientist, Medicinal Chemistry at Microcide Pharmaceuticals Inc. based in Mountain View, California.
Dr. Crawford received his B.Sc. in chemistry/biochemistry in 1991, and a PhD in organic chemistry in 1996 from the University of Victoria (Canada). He then conducted post-doctoral research in organic synthesis at the Ohio State University from 1996-1997.
Doug Erfle, Director, Project Management
Mr. Erfle is a certified project management professional (PMP) with over 15 years of industrial drug development experience. Previously he was director of project management at MIGENIX Inc., a public biopharmaceutical company primarily involved in the development of drugs for the treatment of infectious disease. In this role Mr. Erfle was responsible for development and implementation of corporate project management processes as well as for leading multidisciplinary project teams for products at various stages of development including discovery, pre-clinical, and clinical. Mr. Erfle began his career at MIGENIX as a technician in the pre-clinical research group, eventually advancing to group leader of pharmacology. In this capacity he was responsible for development and execution of plans to evaluate the in-vivo efficacy, safety, and pharmacokinetics of novel drug candidates.
Prior to MIGENIX Mr. Erfle worked in the Biomaterials Laboratory of the Cardiovascular Devices Division at the University of Ottawa Heart Institute. He has an undergraduate degree in applied chemistry from the University of Guelph and masters degree in Biochemistry from the University of Ottawa, as well as a masters certificate in project management from the Schulich School of Business at the University of Victoria.
Barry Gee, Director, Communications and External Affairs
A seasoned professional with a broad background, Mr. Gee has more than 15 years experience in public, media, government and stakeholder relations; communications and marketing; project management; and not-for-profit operations.
Prior to joining CDRD, he spent 10 years as the Senior Director of Operations and Communications at LifeSciences BC, the not-for-profit industry association responsible for representing the province’s life sciences community, and for building the local, national and international partnerships it requires to flourish. In this role, he was responsible for overseeing the successful implementation of all of LSBC’s communications activities as well as a broad suite of programs, events, and services for member organizations.
Mr. Gee completed a Bachelor of Arts Degree in Creative Writing at the University of Victoria in 1993, and began his career as a Communications Officer with the Canadian Forest Research Centre in Victoria. He subsequently joined the Science Council of British Columbia (now BCIC) administering their various funding programs for researchers and technology start-ups. He is also a graduate of the Leadership Vancouver Program, and From Lab to Leadership – Developing Scientific and Corporate Leaders. He has also been a Guest Lecturer with University of British Columbia’s Career Services; Industry Mentor for the Student Biotechnology Network; and has participated on numerous advisory committees including the Executive Committee of the High Tech Communicators’ Exchange, the BIO International Steering Committee, and as a Founding Member of the Global Bioscience Partnership.
Jon Jafari, Senior Director, Business Development
As Senior Director, Business Development, Mr. Jafari has been involved in many of CDRD’s startups, including Kairos Therapeutics (which was sold to Zymeworks), Sitka Biopharma, and Zucara. In addition he is the Chief Business Officer and interim Chief Executive Officer for Sepset Biosciences. Prior to joining CDRD, he spent eight years in progressive business development and strategic marketing roles at QLT Inc. Prior to QLT, Mr. Jafari worked for Eli Lilly in the Business Development Market Assessment group and provided market evaluations and sales forecasts for licensing and M&A opportunities. Mr. Jafari also had research roles at Indiana University in molecular evolution and in tumor targeting at Genetic Therapy Inc., which was a gene therapy company that was acquired by Sandoz, now Novartis.
Mr. Jafari received his BSc Biology and MBA from Indiana University and his MSc Biotechnology from Johns Hopkins University.
Dave Rogers, Senior Director, Intellectual Property
Dr. Dave Rogers joined CDRD as its Intellectual Property Director in January 2011. He has been involved in biotech patent law, particularly US patent law, since completion of his graduate research work in 1999. In 2000, he joined the San Francisco law firm of Flehr, Hohbach, Test, Albritton & Herbert LLP, which was later acquired by Dorsey and Whitney LLP. While working in San Francisco for Dorsey, he qualified as a patent agent before the US Patent and Trademark Office. In 2005, Dr. Rogers relocated to Dorsey’s Vancouver office, continuing to work closely with the San Francisco and Palo Alto offices to advise US and Canadian biotech clients on patent matters.
He has a background in biochemistry, chemistry, immunology, and neurobiology, and his IP experience includes patent drafting, patent prosecution, portfolio evaluation and development, patent analysis and opinion work (freedom to operate, invalidity, and non-infringement) and IP due diligence for licensing and financing. Dr. Rogers received a PhD from the Department of Neurology and Neurosurgery at McGill University in 1999, and a JD from the University of British Columbia in 2013.
Patricia York, Head, Human Resources
A highly experienced human resources professional with a wide range of experience, Patricia brings a wealth of knowledge and skill to CDRD. As Vice President, Human Resources for Disney Interactive Studios in Los Angeles, California previously, she was responsible for operations in the US, Canada, Europe, and Asia, and was instrumental in growing the Vancouver start up studio from five employees to 200 employees in two years. As Head of Human Resources at Electronic Arts Canada, Patricia developed leading edge programs and revamped their recruiting practices to lead the company to a placement on the Globe and Mail’s “50 Best Companies to Work for in Canada” list.